Pharmaceutical Formulations

The author received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

The author spent seven years and 18,000 hours to study, analyze and research his chronic disease conditions. Here is the comparison between 2010 and 2017: Weight: 205 / 172 lbs. Waistline: 44 / 34 inches PPG: 350 / 116 mg/dL FPG: 185 / 119 mg/dL Daily glucose: 280 / 117 mg/dL A1C: 10.0 / 6.1 % ACR: 116 / 12 mg/mmol Triglycerides: 1161 / 69 mg/dL He used mathematics, physics, engineering modeling, and computer science (big data analytics and AI) to derive the mathematical metabolism model and three prediction tools for weight, FPG, and PPG with >30 input elements. This study includes 11 categories: weight, glucose, blood pressure, lipids, food, water, exercise, sleep, stress, life pattern regularity, time, with ~500 input and output elements.

Dr Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980. Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences, National Center for Immunology (Russia), NIH, Bethesda, USA, and British Society for Immunology to cover 4 British university facilities.

A Researcher-immunologist.

Jean-Michel Scherrmann, Pharm. D., Ph. D. is professor in the department of Pharmacokinetics, Faculty of Pharmacy, the University Paris Descartes. He has led the Neuropsychopharmacology Unit at the French Institute of Health and Medical Research (INSERM) and the National Center of Scientific Research (CNRS) from 2002 to 2013. He has been recently promoted Dean of the Faculty of Pharmacy at University Paris Descartes and nominated Professor at the National Institute of Nuclear Sciences and Techniques.

Pharmacokinetics, neuropharmacokinetics, Pharmacology & Toxicology, Neuroscience & Behavior

Ke-He Ruan is Professor of Medicinal Chemistry & Pharmacology and he is Director for Center for Experimental Therapeutics and Pharmacoinformatics (CETP)

Signaling Molecules and Drugs, Drug targets, Molecular Mechanisms, Biomedical field

Adalberto Rezende Santos is Ph.D in Cellular and Molecular Biology from Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Actually, he is a Senior Investigator and Head of the Laboratory of Molecular Biology Applied to Mycobacteria of Oswaldo Cruz Institute, Supervisor at the post-graduation programs of Cellular, Molecular Biology, and Clinical Medicine from Fiocruz and Federal University of Rio de Janeiro respectively. He is ad hoc consultant of the Executive Secretariat of Science Technology and Environment and of the Ministry of Health, Brazil. He is also referee of the Journal of Infectious Diseases and Pharmacogenomics.

Pharmacogenomics, Drug discovery

Dr. Mostafa Norizadeh Tazehkand from Iran (Mioandoab-Qushachay) is currently working as an Assistant Professor in Pharmaceutical Biotechnology department, Bulent Ecevit University, Zonguldak, Turkey. He completed his B.Sc. in Molecular and Cell Biology at Tonekabon University, Iran. Later in 2012, he graduated with M.Sc. in Biotechnology at Cukurova University, Turkey. Dr. Mostafa did his PhD. in Biotechnology at Cukurova University, Turkey in the year 2016. He has published several papers (More than 30) in reputed journals and has participated in several international conferences. He is working as an editorial member in almost 35 scientific journals. His research interests include Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Cloning, Study of chromosomal and genetic abnormalities.

Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Study of chromosomal and genetic abnormalities.

Dr Joël Richard is currently Senior Vice President, Peptides in IPSEN (France). He is globally leading all the pharmaceutical development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several previous global senior positions in various Biotech and Pharma companies, such as: - Vice President, Drug Product Development in Ipsen (France) (2008-2011), - Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), - Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), - COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001). Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials & Colloidal Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1994).

In the last 20 years, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields: polymers, colloids and interfaces, drug delivery, biodegradable microspheres, microencapsulation, supercritical fluids, protein formulations and post-translational modifications, nanoparticles, sustained-release formulations. He is the author of more than 120 international communications and 53 patent families.

Prof. Dr. Christopher Brown, Ph.D., D.Sc., CC, AOE, FRS is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He is an American analytical and organic chemist, who pioneered a number of discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose. His contributions include the discovery of the anomeric effect and the development of general methodologies for the synthesis of saccharides still employed in the area of Nucleic Acids Chemistry. He was a fellow of the American Chemical Society (ACS) and also the Royal Society of Chemistry (England), and a recipient of the prestigious Albert Einstein World Award of Science and Wolf Prize in Chemistry. Furthermore, he is currently Dean of the Faculty of Chemistry at California South University (CSU), Irvine, California, USA.

Discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose and saccharides